BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 38580317)

  • 1. Channeling Nicotinamide Phosphoribosyltransferase (NAMPT) to Address Life and Death.
    Velma GR; Krider IS; Alves ETM; Courey JM; Laham MS; Thatcher GRJ
    J Med Chem; 2024 Apr; 67(8):5999-6026. PubMed ID: 38580317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis, Optimization, and Structure-Activity Relationships of Nicotinamide Phosphoribosyltransferase (NAMPT) Positive Allosteric Modulators (N-PAMs).
    Shen Z; Ratia K; Krider I; Ackerman-Berrier M; Penton C; Musku SR; Gordon-Blake JM; Laham MS; Christie N; Ma N; Fu J; Xiong R; Courey JM; Velma GR; Thatcher GRJ
    J Med Chem; 2023 Dec; 66(24):16704-16727. PubMed ID: 38096366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism of Allosteric Modulation of Nicotinamide Phosphoribosyltransferase to Elevate Cellular NAD
    Ratia KM; Shen Z; Gordon-Blake J; Lee H; Laham MS; Krider IS; Christie N; Ackerman-Berrier M; Penton C; Knowles NG; Musku SR; Fu J; Velma GR; Xiong R; Thatcher GRJ
    Biochemistry; 2023 Feb; 62(4):923-933. PubMed ID: 36746631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nicotinamide phosphoribosyltransferase (Nampt) in carcinogenesis: new clinical opportunities.
    Chen H; Wang S; Zhang H; Nice EC; Huang C
    Expert Rev Anticancer Ther; 2016 Aug; 16(8):827-38. PubMed ID: 27186719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological inhibition of nicotinamide phosphoribosyltransferase (NAMPT), an enzyme essential for NAD+ biosynthesis, in human cancer cells: metabolic basis and potential clinical implications.
    Tan B; Young DA; Lu ZH; Wang T; Meier TI; Shepard RL; Roth K; Zhai Y; Huss K; Kuo MS; Gillig J; Parthasarathy S; Burkholder TP; Smith MC; Geeganage S; Zhao G
    J Biol Chem; 2013 Feb; 288(5):3500-11. PubMed ID: 23239881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of Nicotinamide Phosphoribosyltransferase (NAMPT), an Enzyme Essential for NAD+ Biosynthesis, Leads to Altered Carbohydrate Metabolism in Cancer Cells.
    Tan B; Dong S; Shepard RL; Kays L; Roth KD; Geeganage S; Kuo MS; Zhao G
    J Biol Chem; 2015 Jun; 290(25):15812-15824. PubMed ID: 25944913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of small-molecule urea derivatives as novel NAMPT inhibitors via pharmacophore-based virtual screening.
    Ozgencil F; Eren G; Ozkan Y; Guntekin-Ergun S; Cetin-Atalay R
    Bioorg Med Chem; 2020 Jan; 28(1):115217. PubMed ID: 31818629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel carbon skeletons activate human NicotinAMide Phosphoribosyl Transferase (NAMPT) enzyme in biochemical assay.
    Almeida KH; Avalos-Irving L; Berardinelli S; Chauvin K; Yanez S
    PLoS One; 2023; 18(3):e0283428. PubMed ID: 36996070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NAMPT in regulated NAD biosynthesis and its pivotal role in human metabolism.
    Burgos ES
    Curr Med Chem; 2011; 18(13):1947-61. PubMed ID: 21517777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD73 protein as a source of extracellular precursors for sustained NAD+ biosynthesis in FK866-treated tumor cells.
    Grozio A; Sociali G; Sturla L; Caffa I; Soncini D; Salis A; Raffaelli N; De Flora A; Nencioni A; Bruzzone S
    J Biol Chem; 2013 Sep; 288(36):25938-25949. PubMed ID: 23880765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SIRT6 deacetylase activity regulates NAMPT activity and NAD(P)(H) pools in cancer cells.
    Sociali G; Grozio A; Caffa I; Schuster S; Becherini P; Damonte P; Sturla L; Fresia C; Passalacqua M; Mazzola F; Raffaelli N; Garten A; Kiess W; Cea M; Nencioni A; Bruzzone S
    FASEB J; 2019 Mar; 33(3):3704-3717. PubMed ID: 30514106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of the Nampt-mediated NAD salvage pathway and its therapeutic implications in pancreatic cancer.
    Ju HQ; Zhuang ZN; Li H; Tian T; Lu YX; Fan XQ; Zhou HJ; Mo HY; Sheng H; Chiao PJ; Xu RH
    Cancer Lett; 2016 Aug; 379(1):1-11. PubMed ID: 27233476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of a novel nicotinamide phosphoribosyl transferase (NAMPT) inhibitor via in silico screening.
    Takeuchi M; Niimi T; Masumoto M; Orita M; Yokota H; Yamamoto T
    Biol Pharm Bull; 2014; 37(1):31-6. PubMed ID: 24389478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic strategy in cancer.
    Sampath D; Zabka TS; Misner DL; O'Brien T; Dragovich PS
    Pharmacol Ther; 2015 Jul; 151():16-31. PubMed ID: 25709099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A fluorometric assay for high-throughput screening targeting nicotinamide phosphoribosyltransferase.
    Zhang RY; Qin Y; Lv XQ; Wang P; Xu TY; Zhang L; Miao CY
    Anal Biochem; 2011 May; 412(1):18-25. PubMed ID: 21211508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nicotinamide phosphoribosyltransferase (NAMPT) inhibitors as therapeutics: rationales, controversies, clinical experience.
    Montecucco F; Cea M; Bauer I; Soncini D; Caffa I; Lasigliè D; Nahimana A; Uccelli A; Bruzzone S; Nencioni A
    Curr Drug Targets; 2013 Jun; 14(6):637-43. PubMed ID: 23531116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SAR and characterization of non-substrate isoindoline urea inhibitors of nicotinamide phosphoribosyltransferase (NAMPT).
    Curtin ML; Heyman HR; Clark RF; Sorensen BK; Doherty GA; Hansen TM; Frey RR; Sarris KA; Aguirre AL; Shrestha A; Tu N; Woller K; Pliushchev MA; Sweis RF; Cheng M; Wilsbacher JL; Kovar PJ; Guo J; Cheng D; Longenecker KL; Raich D; Korepanova AV; Soni NB; Algire MA; Richardson PL; Marin VL; Badagnani I; Vasudevan A; Buchanan FG; Maag D; Chiang GG; Tse C; Michaelides MR
    Bioorg Med Chem Lett; 2017 Aug; 27(15):3317-3325. PubMed ID: 28610984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retinal toxicity, in vivo and in vitro, associated with inhibition of nicotinamide phosphoribosyltransferase.
    Zabka TS; Singh J; Dhawan P; Liederer BM; Oeh J; Kauss MA; Xiao Y; Zak M; Lin T; McCray B; La N; Nguyen T; Beyer J; Farman C; Uppal H; Dragovich PS; O'Brien T; Sampath D; Misner DL
    Toxicol Sci; 2015 Mar; 144(1):163-72. PubMed ID: 25505128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Supplementation of nicotinic acid with NAMPT inhibitors results in loss of in vivo efficacy in NAPRT1-deficient tumor models.
    O'Brien T; Oeh J; Xiao Y; Liang X; Vanderbilt A; Qin A; Yang L; Lee LB; Ly J; Cosino E; LaCap JA; Ogasawara A; Williams S; Nannini M; Liederer BM; Jackson P; Dragovich PS; Sampath D
    Neoplasia; 2013 Dec; 15(12):1314-29. PubMed ID: 24403854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EWS-FLI1 confers exquisite sensitivity to NAMPT inhibition in Ewing sarcoma cells.
    Mutz CN; Schwentner R; Aryee DNT; Bouchard EDJ; Mejia EM; Hatch GM; Kauer MO; Katschnig AM; Ban J; Garten A; Alonso J; Banerji V; Kovar H
    Oncotarget; 2017 Apr; 8(15):24679-24693. PubMed ID: 28160567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.